JO2985B1 - مثبطات كينازmapk/erk - Google Patents

مثبطات كينازmapk/erk

Info

Publication number
JO2985B1
JO2985B1 JOP/2007/0555A JOP20070555A JO2985B1 JO 2985 B1 JO2985 B1 JO 2985B1 JO P20070555 A JOP20070555 A JO P20070555A JO 2985 B1 JO2985 B1 JO 2985B1
Authority
JO
Jordan
Prior art keywords
mapk
kinase inhibitors
compounds
erk kinase
methods
Prior art date
Application number
JOP/2007/0555A
Other languages
English (en)
Inventor
Toufike Kanouni
Xianchong Gong
Stephen W Kaldor
Feng Zhou
Qing Dong
Michael B Wallace
Nicholas Scorah
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Application granted granted Critical
Publication of JO2985B1 publication Critical patent/JO2985B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

يتعلق الاختراع الحالي بمركبات ( compounds) من الصيغه التالية للاستخدام مع MEK التي تشمل: حيث تكون المتغيرات كما تحدد هنا، كما يوفر ايضا تركيبات دوائية ( pharmaceutical compositions) مجموعات ( kits) وادوات ( articles) للتصنيع تشمل هذه المركبات ( compounds) الطرق ( methods) والمركبات الوسطية ( intermediates) المفيدة لتصنيع المركبات ( compounds) وطرق ( methods) لاستخدام المركبات( compounds) المذكورة.
JOP/2007/0555A 2006-12-20 2007-12-17 مثبطات كينازmapk/erk JO2985B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US87091306P 2006-12-20 2006-12-20

Publications (1)

Publication Number Publication Date
JO2985B1 true JO2985B1 (ar) 2016-09-05

Family

ID=39462025

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2007/0555A JO2985B1 (ar) 2006-12-20 2007-12-17 مثبطات كينازmapk/erk

Country Status (35)

Country Link
US (4) US8293901B2 (ar)
EP (1) EP2125810B1 (ar)
JP (1) JP5513127B2 (ar)
KR (1) KR101488467B1 (ar)
CN (1) CN101679411B (ar)
AR (1) AR064640A1 (ar)
AU (1) AU2007337003B2 (ar)
BR (1) BRPI0720525B8 (ar)
CA (1) CA2673647C (ar)
CL (1) CL2007003742A1 (ar)
CO (1) CO6230984A2 (ar)
CR (1) CR10937A (ar)
DK (1) DK2125810T3 (ar)
EA (1) EA016312B1 (ar)
EC (1) ECSP099529A (ar)
ES (1) ES2430966T3 (ar)
GE (1) GEP20125511B (ar)
HR (1) HRP20130684T1 (ar)
IL (1) IL199362A (ar)
JO (1) JO2985B1 (ar)
MA (1) MA31151B1 (ar)
MX (1) MX2009006675A (ar)
MY (1) MY157871A (ar)
NO (1) NO342270B1 (ar)
NZ (1) NZ578310A (ar)
PE (1) PE20090071A1 (ar)
PL (1) PL2125810T3 (ar)
PT (1) PT2125810E (ar)
RS (1) RS52887B (ar)
SI (1) SI2125810T1 (ar)
TN (1) TN2009000249A1 (ar)
TW (1) TWI396538B (ar)
UA (1) UA98479C2 (ar)
WO (1) WO2008079814A2 (ar)
ZA (1) ZA200904682B (ar)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1790649A1 (en) * 2005-11-21 2007-05-30 Sanofi-Aventis Substituted bicyclic pyrimidone derivatives
TW200800997A (en) * 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
KR20090071666A (ko) * 2006-10-23 2009-07-01 다케다 야쿠힌 고교 가부시키가이샤 Ｍａｐｋ／ｅｒｋ 키나아제 억제제
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
SA08280783B1 (ar) * 2007-01-11 2011-04-24 استرازينيكا ايه بي مشتقات بيريدوبيريميدين كمثبطات pde4
JP5363350B2 (ja) 2007-03-19 2013-12-11 武田薬品工業株式会社 Ｍａｐｋ／ｅｒｋキナーゼ阻害剤
CA2705452C (en) * 2007-11-12 2016-05-31 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
US20090246198A1 (en) * 2008-03-31 2009-10-01 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
CN102216274A (zh) * 2008-11-18 2011-10-12 武田药品工业株式会社 (R)-3-(2,3-二羟基丙基)-6-氟-5-(2-氟-4-碘苯基氨基)-8-甲基吡啶并[2,3-d]嘧啶-4,7(3H,8H)-二酮及其中间体的制备方法
EP2588107A1 (en) 2010-07-01 2013-05-08 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
TWI505828B (zh) * 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
AR086656A1 (es) * 2011-06-03 2014-01-15 Millennium Pharm Inc Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a
DK3321262T3 (da) 2012-03-01 2021-01-25 Array Biopharma Inc Serin-/threoninkinasehæmmere
CN104428001A (zh) * 2012-03-30 2015-03-18 武田药品工业有限公司 Raf抑制剂和mek抑制剂在黑素瘤治疗中的投与
JP6386177B2 (ja) * 2014-06-17 2018-09-05 ツーセン ファーマシューティカル カンパニー リミテッド ｍＴＯＲ／ＰＩ３Ｋ阻害剤としてのピリド［１，２−ａ］ピリミジノン類似体
WO2016009306A1 (en) * 2014-07-15 2016-01-21 Lupin Limited Heterocyclyl compounds as mek inhibitors
KR101671404B1 (ko) * 2014-09-02 2016-11-02 한국원자력의학원 항암 효과, 방사선 병용치료 효과 및 당뇨병 치료 효과를 갖는 피리미딘 유도체 및 이의 의학적 용도
JP2016155776A (ja) * 2015-02-24 2016-09-01 学校法人兵庫医科大学 抗腫瘍効果増強剤および抗腫瘍剤
ES2876293T3 (es) * 2017-06-23 2021-11-12 Cstone Pharmaceuticals Compuesto cíclico similar a la cumarina como inhibidor de MEK y uso del mismo
GB201713975D0 (en) 2017-08-31 2017-10-18 Macrophage Pharma Ltd Medical use
CA3120337A1 (en) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Naphthyridinone-aniline compounds for treatment of dermal disorders
TWI825637B (zh) 2021-03-31 2023-12-11 美商輝瑞股份有限公司 啶－１，６（２ｈ，７ｈ）－二酮
JP2024047569A (ja) * 2022-09-26 2024-04-05 ファイザー・インク Ｍｅｋ阻害剤としての３，４－ジヒドロ－２，７－ナフチリジン－１，６（２ｈ，７ｈ）－ジオン
CN117779203B (zh) * 2024-02-28 2024-05-31 西北工业大学 一种n-苄基-2-甲基-4-硝基苯胺单晶及其制备方法和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5430148A (en) 1992-03-31 1995-07-04 Agouron Pharmaceuticals, Inc. Antiproliferative quinazolines
IL117923A (en) 1995-05-03 2000-06-01 Warner Lambert Co Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
HRP20010524A2 (en) 1999-01-13 2002-08-31 Warner Lambert Co Benzoheterocycles and their use as mek inhibitors
CA2397961C (en) 2000-01-25 2008-08-26 Richard John Booth Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
CA2416685C (en) 2000-07-19 2008-10-07 Warner-Lambert Company Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
JP4524072B2 (ja) 2000-10-23 2010-08-11 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 新規化合物
US6825180B2 (en) 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
RU2300528C2 (ru) 2002-03-13 2007-06-10 Эррэй Биофарма, Инк. N3-алкилированные бензимидазольные производные в качестве ингибиторов мек
DE60330227D1 (de) 2002-03-13 2010-01-07 Array Biopharma Inc N3-alkylierte benzimidazol-derivate als mek-hemmer
ES2316985T3 (es) 2003-05-23 2009-04-16 Aterna Zentaris Gmbh Nuevas piridopirazidinas y su uso como moduladores de quinasas.
AU2003277715A1 (en) 2003-07-03 2005-01-21 Sunghag Koo Ferment ginseng oil
EP1651214B1 (en) 2003-07-24 2009-09-16 Warner-Lambert Company LLC Benzimidazole derivatives as mek inhibitors
BRPI0413005A (pt) 2003-07-29 2006-09-26 Irm Llc compostos e composições como inibidores da proteìna cinase
CN1905873A (zh) 2003-11-19 2007-01-31 阵列生物制药公司 Mek的杂环抑制剂及其使用方法
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
JP4163738B2 (ja) 2004-06-11 2008-10-08 日本たばこ産業株式会社 癌の治療用の５−アミノ−２，４，７−トリオキソ−３，４，７，８−テトラヒドロ−２Ｈ−ピリド’２，３−ｄ！ピリミジン誘導体及び関連化合物
DE102004054215A1 (de) 2004-11-10 2006-05-11 Merck Patent Gmbh Pyridopyrimidinonderivate
ATE443063T1 (de) 2004-12-01 2009-10-15 Merck Serono Sa Ä1,2,4ütriazoloä4,3-aüpyridin-derivative zur behandlung hyperproliferativer erkrankungen
WO2008010964A1 (en) 2006-07-17 2008-01-24 Merck & Co., Inc. 1-hydroxy naphthyridine compounds as anti-hiv agents
KR20090071666A (ko) 2006-10-23 2009-07-01 다케다 야쿠힌 고교 가부시키가이샤 Ｍａｐｋ／ｅｒｋ 키나아제 억제제
JP2010509265A (ja) 2006-11-09 2010-03-25 エフ．ホフマン−ラ ロシュ アーゲー キナーゼ阻害剤としての置換６−フェニル−ピリド［２，３−ｄ］ピリミジン−７−オン誘導体及びそれの使用方法
JO2985B1 (ar) * 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
CA2705452C (en) 2007-11-12 2016-05-31 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
US20090246198A1 (en) 2008-03-31 2009-10-01 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors and methods of use thereof
CN102216274A (zh) * 2008-11-18 2011-10-12 武田药品工业株式会社 (R)-3-(2,3-二羟基丙基)-6-氟-5-(2-氟-4-碘苯基氨基)-8-甲基吡啶并[2,3-d]嘧啶-4,7(3H,8H)-二酮及其中间体的制备方法

Also Published As

Publication number Publication date
NO342270B1 (no) 2018-04-30
MA31151B1 (ar) 2010-02-01
BRPI0720525B1 (pt) 2020-03-03
HRP20130684T1 (en) 2013-10-11
US20110065733A1 (en) 2011-03-17
AU2007337003B2 (en) 2013-05-02
PL2125810T3 (pl) 2013-09-30
JP2010514680A (ja) 2010-05-06
BRPI0720525A2 (pt) 2014-01-07
AU2007337003A2 (en) 2009-07-30
TWI396538B (zh) 2013-05-21
GEP20125511B (en) 2012-05-10
EP2125810A2 (en) 2009-12-02
KR101488467B1 (ko) 2015-01-30
CA2673647C (en) 2016-02-09
CN101679411B (zh) 2013-04-17
CN101679411A (zh) 2010-03-24
EA016312B1 (ru) 2012-04-30
BRPI0720525B8 (pt) 2021-05-25
RS52887B (sr) 2014-02-28
NZ578310A (en) 2012-01-12
CR10937A (es) 2009-11-20
WO2008079814A3 (en) 2008-09-04
AU2007337003A1 (en) 2008-07-03
US20080255160A1 (en) 2008-10-16
AR064640A1 (es) 2009-04-15
TW200835496A (en) 2008-09-01
ES2430966T3 (es) 2013-11-22
CO6230984A2 (es) 2010-12-20
IL199362A (en) 2013-07-31
US8293901B2 (en) 2012-10-23
CA2673647A1 (en) 2008-07-03
EP2125810B1 (en) 2013-04-24
UA98479C2 (en) 2012-05-25
NO20092692L (no) 2009-09-16
PE20090071A1 (es) 2009-04-04
TN2009000249A1 (en) 2010-10-18
ECSP099529A (es) 2009-08-28
JP5513127B2 (ja) 2014-06-04
SI2125810T1 (sl) 2013-09-30
MX2009006675A (es) 2009-08-12
EA200970605A1 (ru) 2009-12-30
US20100130518A1 (en) 2010-05-27
WO2008079814A2 (en) 2008-07-03
KR20090091353A (ko) 2009-08-27
DK2125810T3 (da) 2013-07-29
CL2007003742A1 (es) 2008-06-13
ZA200904682B (en) 2010-09-29
US8470837B2 (en) 2013-06-25
US8030317B2 (en) 2011-10-04
PT2125810E (pt) 2013-07-29
MY157871A (en) 2016-07-29
US20120202999A1 (en) 2012-08-09

Similar Documents

Publication Publication Date Title
JO2985B1 (ar) مثبطات كينازmapk/erk
WO2008115890A3 (en) Mapk/erk kinase inhibitors
WO2009146034A3 (en) Mapk/erk kinase inhibitors and methods of use thereof
TN2010000131A1 (en) Polo-like kinase inhibitors
MY150542A (en) Cmet inhibitors
WO2007117995A3 (en) Kinase inhibitors
WO2008079787A8 (en) Glucokinase activators
WO2007104034A3 (en) Glucokinase activators
MY146989A (en) Kinase inhibitors
ATE479687T1 (de) Kinaseinhibitoren
WO2008116107A3 (en) Piperazine derivatives as glucokinase activators
WO2008053194A3 (en) Pyridine carboxamides as 11-beta-hsd1 inhibitors
WO2008055236A3 (en) Mapk/erk kinase inhibitors
WO2010111626A3 (en) Poly (adp-ribose) polymerase (parp) inhibitors
MX339476B (es) Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
WO2010008847A3 (en) Pi3k/m tor inhibitors
WO2009140624A3 (en) Glucokinase activators
PT2470546E (pt) Compostos de hexa-hidrooxazinopteridina para serem utilizados como inibidores de mtor
TN2009000151A1 (en) Mapk/erk kinase inhibitors
JO2822B1 (ar) مثبطات إنزيم كيناز p70 s6و akt
WO2008054956A3 (en) Kinase inhibitors
WO2009129401A8 (en) Kinase inhibitors
WO2008045834A3 (en) Kinase inhibitors
WO2008089005A3 (en) Renin inhibitors
TN2009000130A1 (en) Kinase inhibitors